Tectonic Therapeutic (TECX) Stock Price, News & Analysis

Company Overview

Tectonic Therapeutic (NASDAQ:TECX) is a clinical‐stage biotechnology company focused on the discovery and development of next‐generation T‐cell engaging antibodies for the treatment of cancer. The company’s proprietary platform integrates advanced antibody engineering, multispecific design and tumor‐targeted binding to recruit and activate T cells directly at the tumor site. By leveraging its T-Cell Engaging Platform, Tectonic Therapeutic aims to create therapies that enhance selectivity and reduce off‐tumor toxicity commonly associated with traditional immunotherapies.

Founded in 2019 and headquartered in South San Francisco, California, Tectonic Therapeutic applies a multidisciplinary approach that combines structural biology, computational design and translational immunology. Its pipeline includes multiple preclinical assets directed against both hematologic malignancies and solid tumors, with lead programs advancing toward investigational new drug (IND) enabling studies. The company’s research strategy emphasizes exploiting novel antigen targets and optimizing pharmacokinetic profiles to improve patient tolerability and therapeutic window.

Since inception, Tectonic Therapeutic has built collaborations with leading academic institutions and oncology research centers across North America and Europe to accelerate target discovery and preclinical validation. The company’s R&D operations are supported by state‐of‐the‐art laboratories in the San Francisco Bay Area, while its development strategy includes scalable manufacturing partnerships to ensure robust clinical supply. These efforts position Tectonic Therapeutic to move key programs through IND filing and into early‐stage clinical trials.

Tectonic Therapeutic is led by a management team with deep expertise in antibody drug development, immuno‐oncology and translational research. The executive leadership is supported by a board of directors and scientific advisory board comprised of industry veterans and academic leaders. Together, they guide the company’s strategic direction, oversee clinical and regulatory planning, and champion collaborative partnerships aimed at delivering novel cancer therapies to patients in need.

Key Stats

• Today's Range: $22.43 to $23.50
• 50-Day Range: $18.75 to $25.16
• 52-Week Range: $13.70 to $61.07
• Volume: 156,896 shs
• Average Volume: 190,873 shs
• Market Capitalization: $434.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $83.60
• Consensus Rating: Buy

Tectonic Therapeutic Stock Analysis - MarketRank™

Tectonic Therapeutic scored higher than 60% of companies evaluated by MarketBeat, and ranked 448th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Tectonic Therapeutic has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Tectonic Therapeutic has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Tectonic Therapeutic are expected to grow in the coming year, from ($8.31) to ($5.10) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tectonic Therapeutic is -3.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tectonic Therapeutic is -3.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tectonic Therapeutic has a P/B Ratio of 2.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.56% of the float of Tectonic Therapeutic has been sold short.

Short Interest Ratio / Days to Cover

Tectonic Therapeutic has a short interest ratio ("days to cover") of 8.4.

Change versus previous month

Short interest in Tectonic Therapeutic has recently increased by 30.60%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tectonic Therapeutic does not currently pay a dividend.

Dividend Growth

Tectonic Therapeutic does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

16.56% of the float of Tectonic Therapeutic has been sold short.

Short Interest Ratio / Days to Cover

Tectonic Therapeutic has a short interest ratio ("days to cover") of 8.4.

Change versus previous month

Short interest in Tectonic Therapeutic has recently increased by 30.60%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Tectonic Therapeutic has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.

MarketBeat Follows

4 people have added Tectonic Therapeutic to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Tectonic Therapeutic insiders have not sold or bought any company stock.

Percentage Held by Insiders

38.00% of the stock of Tectonic Therapeutic is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

62.63% of the stock of Tectonic Therapeutic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TECX Stock Analysis - Frequently Asked Questions

How have TECX shares performed this year?

Tectonic Therapeutic's stock was trading at $46.17 at the beginning of 2025. Since then, TECX stock has decreased by 49.6% and is now trading at $23.28.

How were Tectonic Therapeutic's earnings last quarter?

Tectonic Therapeutic, Inc. (NASDAQ:TECX) issued its quarterly earnings data on Thursday, May, 8th. The company reported ($0.93) earnings per share for the quarter, topping the consensus estimate of ($1.10) by $0.17.

How do I buy shares of Tectonic Therapeutic?

Shares of TECX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Tectonic Therapeutic own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tectonic Therapeutic investors own include Waste Connections (WCN), iShares Micro-Cap ETF (IWC), The RMR Group (RMR), DiamondRock Hospitality (DRH), AU Optronics (AUOTY), American Water Works (AWK) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/17/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TECX
• Previous Symbol: NASDAQ:TECX
• CIK: 1681087
• Web: www.avrobio.com
• Phone: 617-914-8420
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Tectonic Therapeutic: $83.60
• High Price Target: $101.00
• Low Price Target: $69.00
• Potential Upside/Downside: +259.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($7.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$57.98 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -30.13%
• Return on Assets: -27.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 22.92
• Quick Ratio: 22.92

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.54 per share
• Price / Book: 2.44

Miscellaneous

• Outstanding Shares: 18,670,000
• Free Float: 11,577,000
• Market Cap: $434.64 million
• Optionable: N/A
• Beta: 3.17